StemCyte was founded in 1997 with the mission to build the largest and most racially diverse public umbilical cord blood (UCB) inventory.
StemCyte delivered it’s 1st and 2nd transplant units to treat a double non-myeloablative multi-unit cord blood transplant in 2001. Dr. Patrick Tan received a President’s Medal for the successful treatment. In 2003, StemCyte hosted the first Umbilical Cord Blood Transplantation Symposium at City of Hope National Cancer Hospital in Los Angeles, CA.
In 2018, StemCyte received FDA approval of its Phase II IND application for allogeneic Human Leukocyte Antigen (HLA) matched umbilical cord blood mononuclear stem cells for the treatment of spinal cord injury.
To date, we have released over 2,200 transplant units. We are proud of our accomplishments.
Dr. Patrick Tan conducted the first successful treatment using UCB Non-Myeloablative Multi-unit Cord Blood (CB) in Singapore. Dr. Tan received the President’s Award for this medal.
StemCyte received banking accreditation in both the United States and Taiwan from AABB.
Additionally, the first-ever Umbilical Cord Blood Transplantation Symposium was hosted by StemCyte at City of Hope National Cancer Hospital in Los Angeles.
Once a public-only venture, StemCyte launched its private banking divisions: one in the United States and one in Taiwan.
In Taiwan, the organization also received an NMDP grant to collect public units, which was the first-ever grant given to a non-USA public bank. Additionally, they receive approval from the Taiwan Food and Drug Administration for a Phase II IND clinical trial for 12 patients diagnosed with Beta-Thalassemia Major.
Meanwhile, in the United States, StemCyte received a US Congress earmark and National Marrow Donor Program (NMDP) to diversify the United States public cord bank inventory.
Dr. Wise Young of Rutgers partnered with StemCyte this year to begin clinical trials with StemCyte’s newly-launched advanced therapeutics division.
They also received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT). They were the first cord blood bank anywhere in the world to receive this accreditation for both Allogeneic and Autologous Banking.
StemCyte was the first private company to become a HRSA partner.
Dr. Wise Young of Rutgers submitted a patent application this year for the combination of UCB cells plus Lithium to promote the secretion of neurotrophic factors that are thought to support the activation of the body’s neural stem cells. This therapy promoted the growth and repair of nerves in the body.
StemCyte expanded to India to partner with The Apollo Hospital Group and Cadila Pharmaceutical. Another patent was submitted this year in the United States for the treatment of brain damage using stem cells.
StemCyte applied for another patent, this time for a method to modify cord blood cells for HIV resistance.
Two clinical trials were started this year: one in Taiwan which used autologous peripheral blood stem cells (CD34+) for the treatment of chronic stroke patients. This trial was completed with an 85% success rate.
The second was started by Dr. Wise Young in Hong Kong, involving the treatment of spinal cord injuries using mononuclear cells from StemCyte units.
StemCyte and Dr. Young began phase II of their spinal cord injury treatment in Hong Kong.
In the United States, StemCyte was awarded a U.S. Patent for its unique Plasma Depletion UCB Processing method.
Additionally, a new partnership was launched this year– a cord blood collection partnership between StemCyte and Sharp HealthCare.
The second phase of Dr. Young’s spinal cord injury treatment was completed in 2012.
StemCyte received TFDA approval for its Phase II IND clinical trial using CD34+ from patients’ peripheral blood for chronic stroke treatment.
During this year, a Chinese patent for the use of Lithium + UCB was awarded to StemCyte.
Additionally, a new partnership was also struck up between UC Davis and StemCyte for a public banking program.
Kaiser and StemCyte partnered together this year to create a new model for cord blood collection.
StemCyte also applied for a US patent through partner Cell Research Corp to store and expand mesenchymal and epithelial cells leading to therapeutic products.
StemCyte opened a new facility in Baldwin Park, California just in time for it to celebrate its 2,000th shipment of a transplant unit.
It was also awarded a patent for Lithium Stimulation of Stem Cells Proliferation and growth factor production in the United States, Europe, China, Japan, Australia, and Korea.
In Japan, StemCyte was awarded a patent for Stem Cell Screening for HIV infection.
StemCyte was also re-accredited by FACT (Foundation for the Accreditation of Cellular Therapy) for both Public and Private Banks. StemCyte was one of the five accredited family banking organizations.
StemCyte celebrated its 20th anniversary as part of the research community.
StemCyte opened two new umbilical cord blood collection sites in Southern California.
In December, the FDA approved the application of their Phase II Investigational New Drug (IND) for Allogeneic Human Leukocyte Antigen (HLA)-matched UBC Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury.
Chief Sales/Marketing Officer
Vice President of Cord Blood Association
CHIEF OF SCIENCE AND MEDICAL ADVISOR
Chief Medical Officer
Chief Medical Officer
Chief Operating Officer